ci 988 has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jensen, RT; Moody, TW; Moreno, P; Nuche-Berenguer, B | 1 |
| Jensen, RT; Moody, TW | 1 |
2 other study(ies) available for ci 988 and Lung Neoplasms
| Article | Year |
|---|---|
CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dipeptides; ErbB Receptors; Gastrins; Gefitinib; Hormone Antagonists; Humans; Indoles; Lung Neoplasms; Meglumine; Pyrimidines; Quinazolines | 2015 |
CI-988 inhibits growth of small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Drug Screening Assays, Antitumor; Humans; Indoles; Lung Neoplasms; Meglumine; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Tumor Cells, Cultured | 2001 |